Reappraisal of the Concept and Implications of Pulmonary Hypertension in Degenerative Mitral Regurgitation.

degenerative mitral regurgitation echocardiography mitral valve prolapse pulmonary hypertension survival

Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
14 Jun 2024
Historique:
received: 14 02 2024
revised: 18 04 2024
accepted: 07 05 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: aheadofprint

Résumé

European and U.S. clinical guidelines diverge regarding pulmonary hypertension (PHTN) in degenerative mitral regurgitation (DMR). Gaps in knowledge underpinning these divergences affect risk assessment and management recommendations attached to systolic pulmonary pressure (SPAP) in DMR. This study sought to define PHTN links to DMR severity, prognostic thresholds, and independent outcome impact in a large quantitative DMR registry. This study gathered a large multicentric registry of consecutive patients with isolated moderate-to-severe DMR, with DMR and SPAP quantified prospectively at diagnosis. In 3,712 patients (67 ± 15 years, 36% women) with ≥ moderate-to-severe DMR, effective regurgitant orifice (ERO) was 0.42 ± 0.19 cm This large international registry, with prospectively quantified DMR and SPAP, demonstrates a Doppler-defined PHTN impact on mortality, independent of DMR severity. Crucially, it defines objectively the new and frequent mPHTN range, independently linked to excess mortality under medical management, which is abolished by DMR correction. Thus, at DMR diagnosis, Doppler-SPAP measurement defining these new PHTN ranges, is crucial to guiding DMR management.

Sections du résumé

BACKGROUND BACKGROUND
European and U.S. clinical guidelines diverge regarding pulmonary hypertension (PHTN) in degenerative mitral regurgitation (DMR). Gaps in knowledge underpinning these divergences affect risk assessment and management recommendations attached to systolic pulmonary pressure (SPAP) in DMR.
OBJECTIVES OBJECTIVE
This study sought to define PHTN links to DMR severity, prognostic thresholds, and independent outcome impact in a large quantitative DMR registry.
METHODS METHODS
This study gathered a large multicentric registry of consecutive patients with isolated moderate-to-severe DMR, with DMR and SPAP quantified prospectively at diagnosis.
RESULTS RESULTS
In 3,712 patients (67 ± 15 years, 36% women) with ≥ moderate-to-severe DMR, effective regurgitant orifice (ERO) was 0.42 ± 0.19 cm
CONCLUSIONS CONCLUSIONS
This large international registry, with prospectively quantified DMR and SPAP, demonstrates a Doppler-defined PHTN impact on mortality, independent of DMR severity. Crucially, it defines objectively the new and frequent mPHTN range, independently linked to excess mortality under medical management, which is abolished by DMR correction. Thus, at DMR diagnosis, Doppler-SPAP measurement defining these new PHTN ranges, is crucial to guiding DMR management.

Identifiants

pubmed: 38934979
pii: S1936-878X(24)00195-5
doi: 10.1016/j.jcmg.2024.05.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures This study was supported by the Mayo Foundation, French Ministry of Health “PHRC-I 2012” (Dr Le Tourneau, API12/N/019), Fédération Française de Cardiologie (Dr Le Tourneau, 2015), and Fondation Cœur et Recherche (Dr Le Tourneau, 2015). The Department of Cardiology of the Leiden University Medical Center received research grants from Abbott Vascular, Bioventrix, Medtronic, Biotronik, Boston Scientific, GE Healthcare, and Edwards Lifesciences. Drs Bax and Ajmone Marsan have received speaker fees from Abbott Vascular. Dr Enriquez-Sarano has received consulting fees from Edwards LLC, Cryolife Inc, ChemImage, and HighLife Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Benjamin Essayagh (B)

Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA; Department of Echocardiography, Cardio X Clinic, Cannes, France.

Giovanni Benfari (G)

Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Clemence Antoine (C)

Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Francesco Grigioni (F)

University Campus Bio-Medico, Department of Cardiology, Rome, Italy.

Thierry Le Tourneau (T)

University of Nantes, Department of Cardiology, Nantes, France.

Jean-Christian Roussel (JC)

University of Nantes, Department of Cardiology, Nantes, France.

Jeroen J Bax (JJ)

Leiden University Medical Center, Department of Cardiology, Leiden, the Netherlands.

Nina Ajmone Marsan (N)

Leiden University Medical Center, Department of Cardiology, Leiden, the Netherlands.

Steele C Butcher (SC)

Leiden University Medical Center, Department of Cardiology, Leiden, the Netherlands; Department of Cardiology. Royal Perth Hospital, Perth, Western Australia, Australia.

Christophe Tribouilloy (C)

University of Amiens, Department of Cardiology, Amiens, France.

Dan Rusinaru (D)

University of Amiens, Department of Cardiology, Amiens, France.

Aviram Hochstadt (A)

Tel Aviv Medical Center and Sackler Faculty of Medicine, Department of Cardiology, Tel Aviv, Israel.

Yan Topilsky (Y)

Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Edward El-Am (E)

Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Prabin Thapa (P)

Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Hector I Michelena (HI)

Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Maurice Enriquez-Sarano (M)

Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA; Abbott Northwestern Hospital, Minneapolis, Minnesota, USA. Electronic address: sarano.maurice@gmail.com.

Classifications MeSH